User login
Key clinical point: In patients newly diagnosed with irritable bowel syndrome (IBS), an 8-week fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP)-lowering diet application was superior to a spasmolytic agent, otilonium bromide (OB), in improving disease symptoms.
Major finding: At 8 weeks, the response rate (71% vs 61%; P = .03) and treatment adherence rate (94% vs 73%; P < .001) were significantly higher in the diet vs OB arm, with the improvement in IBS Symptom Severity Score being significantly higher in the diet group (P = .02). No serious adverse reactions were recorded.
Study details: Findings are from the DOMINO trial that included 459 primary care patients with IBS who were randomly assigned to the 8-week OB (40 mg, 3 times/day) or FODMAP-lowering diet application group.
Disclosures: This study was funded through the Belgian Health Care Knowledge Centre and others. The authors declared serving as scientific advisors or on speaker bureaus or receiving research support or grants from various sources.
Source: Carbone F et al. Diet or medication in primary care patients with IBS: The DOMINO study - a randomized trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute. Gut. 2022 (Apr 28). Doi: 10.1136/gutjnl-2021-325821
Key clinical point: In patients newly diagnosed with irritable bowel syndrome (IBS), an 8-week fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP)-lowering diet application was superior to a spasmolytic agent, otilonium bromide (OB), in improving disease symptoms.
Major finding: At 8 weeks, the response rate (71% vs 61%; P = .03) and treatment adherence rate (94% vs 73%; P < .001) were significantly higher in the diet vs OB arm, with the improvement in IBS Symptom Severity Score being significantly higher in the diet group (P = .02). No serious adverse reactions were recorded.
Study details: Findings are from the DOMINO trial that included 459 primary care patients with IBS who were randomly assigned to the 8-week OB (40 mg, 3 times/day) or FODMAP-lowering diet application group.
Disclosures: This study was funded through the Belgian Health Care Knowledge Centre and others. The authors declared serving as scientific advisors or on speaker bureaus or receiving research support or grants from various sources.
Source: Carbone F et al. Diet or medication in primary care patients with IBS: The DOMINO study - a randomized trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute. Gut. 2022 (Apr 28). Doi: 10.1136/gutjnl-2021-325821
Key clinical point: In patients newly diagnosed with irritable bowel syndrome (IBS), an 8-week fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP)-lowering diet application was superior to a spasmolytic agent, otilonium bromide (OB), in improving disease symptoms.
Major finding: At 8 weeks, the response rate (71% vs 61%; P = .03) and treatment adherence rate (94% vs 73%; P < .001) were significantly higher in the diet vs OB arm, with the improvement in IBS Symptom Severity Score being significantly higher in the diet group (P = .02). No serious adverse reactions were recorded.
Study details: Findings are from the DOMINO trial that included 459 primary care patients with IBS who were randomly assigned to the 8-week OB (40 mg, 3 times/day) or FODMAP-lowering diet application group.
Disclosures: This study was funded through the Belgian Health Care Knowledge Centre and others. The authors declared serving as scientific advisors or on speaker bureaus or receiving research support or grants from various sources.
Source: Carbone F et al. Diet or medication in primary care patients with IBS: The DOMINO study - a randomized trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute. Gut. 2022 (Apr 28). Doi: 10.1136/gutjnl-2021-325821